Neximmune announces closing of $3.67 million registered direct offering priced at-the-market under nasdaq rules

Gaithersburg, md., feb. 06, 2024 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under nasdaq rules.
NEXI Ratings Summary
NEXI Quant Ranking